Detalhe da pesquisa
1.
A Prediction Model for Successful Increase of Adalimumab Dose Intervals in Patients with Crohn's Disease: Secondary Analysis of the Pragmatic Open-Label Randomised Controlled Non-inferiority LADI Trial.
Dig Dis Sci
; 2024 Apr 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38594435
2.
Early fecal calprotectin levels at week 8 may guide therapeutic decisions on Ustekinumab therapy in patients with Crohn's disease.
Scand J Gastroenterol
; 58(9): 980-987, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36970968
3.
Prediction of Relapse After Anti-Tumor Necrosis Factor Cessation in Crohn's Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies.
Clin Gastroenterol Hepatol
; 20(8): 1671-1686.e16, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33933376
4.
Discontinuation of Anti-Tumour Necrosis Factor Therapy in Patients with Perianal Fistulizing Crohn's Disease: Individual Participant Data Meta-Analysis of 309 Patients from 12 Studies.
J Crohns Colitis
; 18(1): 134-143, 2024 Jan 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-37437094
5.
Modulation of Indoleamine 2,3-Dioxygenase 1 During Inflammatory Bowel Disease Activity in Humans and Mice.
Int J Tryptophan Res
; 16: 11786469231153109, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36798536
6.
Ustekinumab Tissue and Serum Levels in Patients With Crohn's Disease Are Closely Correlated Though Not Consistently Associated With Objective Response After Induction.
Inflamm Bowel Dis
; 29(7): 1038-1046, 2023 07 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-35917118
7.
Increased versus conventional adalimumab dose interval for patients with Crohn's disease in stable remission (LADI): a pragmatic, open-label, non-inferiority, randomised controlled trial.
Lancet Gastroenterol Hepatol
; 8(4): 343-355, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36736339
8.
Cost-Effectiveness Analysis of Increased Adalimumab Dose Intervals in Crohn's Disease Patients in Stable Remission: The Randomized Controlled LADI Trial.
J Crohns Colitis
; 17(11): 1771-1780, 2023 Nov 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-37310877
9.
Vedolizumab Tissue Concentration Correlates to Mucosal Inflammation and Objective Treatment Response in Inflammatory Bowel Disease.
Inflamm Bowel Dis
; 27(11): 1813-1820, 2021 10 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-33705545
10.
Fecal calprotectin is an early predictor of endoscopic response and histologic remission after the start of vedolizumab in inflammatory bowel disease.
Therap Adv Gastroenterol
; 13: 1756284820979765, 2020.
Artigo
em Inglês
| MEDLINE | ID: mdl-33488771
11.
Comment on "Predictors and Management of Loss of Response to Vedolizumab in Inflammatory Bowel Disease".
Inflamm Bowel Dis
; 25(5): e59, 2019 04 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31222304